← Russell 3000 cross-section

CNMD CONMED Corp

Trailing twelve months to 2025-12-31 · as filed 2026-02-17, not restated
Healthcare

Scale

Market cap
$1.5bn
Revenue TTM
$1.4bn
Net income TTM
$47m
Free cash flow
$151m
Composite score
75.5
Sector rank
#1786

Valuation

P / E
32.3
EV / EBITDA
9.8
EV / sales
1.1
FCF yield
9.92%
Earnings yield vs 10-yr
-1.63pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
3.4%
EBITDA margin
11.3%
ROE
4.5%
ROIC
9.9%
Revenue growth
5.2%

Insider activity, last 90 days

Net open-market
$0.00m
Buyers
0
Sellers
0

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

These product lines as a percentage of consolidated net sales are as follows: A significant amount of our products are used in surgical procedures with approximate ly 86% of our revenues derived from the sale of single-use products. International sales approximated 47% and 44% of our consolidated net sales duri ng the six months ended June 30, 2026 and 2025, respectively. Consolidated Results of Operations The following table presents, as a percentage of net sales, certain categories included in our consolidated condensed statements of comprehensive income for the periods indicated: Net Sales The following table presents net sales by product line (in millions) for the three and six months en …CONMED Corp, 10-Q, period ended 2026-06-30, filed 2026-07-29

Read the full passage →